​

Dermata Therapeutics Stock (NASDAQ:DRMA)

OwnershipFinancialsChart
Dermata Therapeutics by TradingView

Previous Close

$1.25

52W Range

$0.95 - $6.22

50D Avg

$1.31

200D Avg

$1.58

Market Cap

$824.68K

Avg Vol (3M)

$752.27K

Beta

0.69

Div Yield

-

DRMA Company Profile

Dermata Therapeutics, Inc. engages in the development and distribution of over-the-counter pharmaceutical dermatology-focused products in the United States. The company develops direct-to-consumer skincare products, including foundation treatment products for skin renewal and clearing treatment products for the treatment of acne under the Tome brand. Dermata Therapeutics, Inc. was incorporated in 2014 and is headquartered in San Diego, California.

Show More

Industry

Biotechnology

Sector

Healthcare

Exchange

NASDAQ

ADR

-

Country

US

Employees

9

IPO Date

Aug 13, 2021

Website

DRMA Performance

DRMA Financial Summary

Dec 25Dec 24Dec 23
Revenue---
Operating Income$-7.77B$-12.51M$-8.04M
Net Income$-7.56B$-12.29M$-7.79M
EBITDA$-7.77B$-12.29M$247.22K
Basic EPS$-8.16$-80.32$-401.80
Diluted EPS$-8.16$-80.32$-399.81

Fiscal year ends in Dec 25 | Currency in USD

Peer Comparison

TickerCompany
ARTLArtelo Biosciences, Inc.
VRAXVirax Biolabs Group Limited
PBMPsyence Biomedical Ltd.
GTBPGT Biopharma, Inc.
ELABPMGC Holdings Inc.
REVBRevelation Biosciences, Inc.
WINTWindtree Therapeutics, Inc.
CARMCarisma Therapeutics, Inc.